PF-04382923

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePF-04382923
Drug Alias NameRN-6GPF-4382923PF-04382923
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsMacular DegenerationRetinal DegenerationEye Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsMacular DegenerationRetinal DegenerationEye Diseases

Other Information

ATC CodeN/A
Related LinksN/A